Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test
As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.
Remote patient monitoring (RPM) of vitals takes away the uncertainty of leaving symptom detection to patients.
Geopolitical risk is now front of mind for many pharmaceutical leaders.
Editor's Picks
